Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-08T12:51:28.577Z Has data issue: false hasContentIssue false
  • English
  • Français

Chlorpromazine and the Untreated Chronic Schizophrenic: A Long-Term Trial

Published online by Cambridge University Press:  29 January 2018

F. J. J. Letemendia  and
A. D. Harris
A. D. Harris
Affiliation:
Littlemore Hospital, Oxford
Get access Rights & Permissions [Opens in a new window]

Extract

Although chlorpromazine was the first of the phenothiazine drugs to be used in psychiatry, and has since been the subject of an extensive literature, there is a surprising dearth of information about the nature of its effect in chronic schizophrenia. Some early reports indicated that it produced a beneficial change, but before this could be examined and documented the attention of most psychiatrists was diverted to newer and supposedly more potent analogues. The present trial was undertaken with three factors in mind, which had not been fully taken into account of in previous studies. These were:

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 502 , September 1967 , pp. 950 - 958
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Forrest, F. M., and Forrest, I. S. (1957). “A simple test for the detection of chlorpromazine in urine.” Am. J. Psychiat., 113, 931–932.Google Scholar
2. Forrest, F. M., and Mason, A. S. (1958). “A rapid urinary test for chlorpromazine, promazine and pacatal: a supplementary report.” Ibid., 114, 931–932.Google ScholarPubMed
3. Harris, A. D., Letemendia, F. J. J., and Willems, P. J. A. (1967). “A rating scale of the mental state: for use in the chronic population of the psychiatric hospital.” Brit. J. Psychiat., 113, 941–949.CrossRefGoogle ScholarPubMed
4. Heilizer, F. (1960). “A critical review of some published experiments with chlorpromazine in schizophrenic, neurotic and normal humans.” J. chron. Dis., 11, 102–148.Google Scholar
5. Letemendia, F. J. J., and Harris, A. D. (1959). “The influence of side-effects on the reporting of symptoms.” Psychopharmacologia, 1, 39–47.CrossRefGoogle ScholarPubMed
6. Letemendia, F. J. J., Harris, A. D., and Willems, P. J. A. (1967). “The clinical effects on a population of chronic schizophrenic patients of administrative changes in hospital.” Brit. J. Psychiat., 113, 959–971.Google Scholar
7. Mayer-Gross, W., Harris, A. D., and Letemendia, F. J. J. (1959). “Comparison of abnormal behavioural states induced by psychotropic drugs in animals and man.” In: Neuro-Psychopharmacology. Proceedings of the 1st International Congress of Neuro-Pharmacology (ed. Bradley, P. B., Deniker, P., and Radouco-Thomas, C.), Amsterdam, etc., 108–115.Google Scholar
8. Pollack, B. (1958). “The validity of the Forrest reagent test for the detection of chlorpromazine or other phenothiazines in the urine.” Am. J. Psychiat., 115, 77–78.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.